grade 3a follicular lymphoma
Showing 1 - 13 of 13
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in United States (Bendamustine
Suspended
- Grade 1 Follicular Lymphoma
- +4 more
- Bendamustine Hydrochloride
- +13 more
-
Anchorage, Alaska
- +422 more
Feb 2, 2023
Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,
Completed
- Grade 3a Follicular Lymphoma
- +9 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2023
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in
Recruiting
- Ann Arbor Stage II Follicular Lymphoma
- +5 more
- Ibrutinib
- +2 more
-
Fresno, California
- +2 more
Jan 24, 2023
B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,
Recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Acalabrutinib
- Axicabtagene Ciloleucel
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 9, 2022
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation
Active, not recruiting
- Grade 1 Follicular Lymphoma
- +6 more
- Ibrutinib
- +2 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
Jun 13, 2022
Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)
Recruiting
- Grade 3a Follicular Lymphoma
- +14 more
- Laboratory Biomarker Analysis
- +2 more
-
Atlanta, Georgia
- +1 more
May 31, 2022
B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma Trial in Palo Alto (biological, other,
Active, not recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Anti-OX40 Antibody BMS 986178
- +3 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
May 3, 2022
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,
Active, not recruiting
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
- +11 more
- Lenalidomide
- +2 more
-
Atlanta, Georgia
- +1 more
Apr 18, 2022
Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 1
Active, not recruiting
- Ann Arbor Stage II Grade 1 Follicular Lymphoma
- +12 more
- Lenalidomide
- Obinutuzumab
-
Houston, TexasM D Anderson Cancer Center
Feb 18, 2022
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma Trial
Active, not recruiting
- Ann Arbor Stage II Follicular Lymphoma
- +9 more
- Ibrutinib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Feb 3, 2022
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Atlanta (drug, biological,
Recruiting
- Grade 1 Follicular Lymphoma
- +7 more
- Acalabrutinib
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Dec 7, 2021
Anemia, B-Cell Prolymphocytic Leukemia, Grade 1 Follicular Lymphoma Trial in Portland (drug, other, biological)
Completed
- Anemia
- +13 more
- Entospletinib
- +3 more
-
Portland, OregonOHSU Knight Cancer Institute
Apr 29, 2021
Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor
Recruiting
- Non-Hodgkin's Lymphoma
- +18 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Mar 11, 2021